“Treatment with Anavex‘s investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their ability to perform daily activities, according to interim data from a Phase 2 extension study.”
Read the Full Story at alzheimersnewstoday.com
Alzheimer’s Extension Study Shows Anavex 2-73 Slows Cognitive Decline
More from ResearchMore posts in Research »
- A possible blood test for early-stage Alzheimer’s disease | Medical Xpress
- Blood Biomarkers Plus Gene Status Predict Cognitive Decline : Neurology Today
- Early Detection of Alzheimer’s Prior to Onset of Symptoms Now Possible | Science Times
- We Need New Ideas for Fighting Alzheimer’s | Scientific American
- Immune view offers clues to early Alzheimer’s